Hepatic steatosis (MASLD): fat in the liver as a metabolic signal
Metabolic dysfunction-associated steatotic liver disease has ceased to be an incidental ultrasound finding and become a central marker of cardiometabolic risk. What the data actually show about diagnosis, prognosis, and management.
From NAFLD to MASLD: a nomenclature based on positive criteria
MASLD is no longer a diagnosis of exclusion: it requires steatosis PLUS a cardiometabolic criterion.
For decades, fat in the liver without an alcoholic cause was called nonalcoholic fatty liver disease (NAFLD), a label defined by what the disease was not. In 2023, a multisociety Delphi panel proposed a new nomenclature: metabolic dysfunction-associated steatotic liver disease, or MASLD (Rinella et al., 2023).
The change is not merely semantic. The diagnosis of MASLD requires the presence of hepatic steatosis (documented by imaging or biopsy) plus at least one of five cardiometabolic criteria. It is therefore a diagnosis by positive criteria, one that explicitly recognizes the metabolic root of the condition, rather than a label defined by the absence of alcohol consumption (Rinella et al., 2023).
Terminological precision matters: MASLD, MetALD (when there is alcohol consumption in intermediate ranges) and MASH (the form with steatohepatitis, formerly NASH) are not interchangeable synonyms. Confusing them leads to errors in stratification. Most patients previously labeled as NAFLD meet the criteria for MASLD, which eases the transition, but correct classification depends on individual assessment.
| Domain | Criterion (example threshold) |
|---|---|
| Adiposity | Overweight/obesity or increased waist circumference |
| Blood glucose | Hyperglycemia, prediabetes, or type 2 diabetes (or treatment) |
| Blood pressure | Arterial hypertension or use of an antihypertensive |
| Triglycerides | Hypertriglyceridemia (or lipid-lowering treatment) |
| HDL cholesterol | Low HDL (or lipid-lowering treatment) |
A common problem, not a rarity
About one in three adults lives with metabolic steatosis.
Metabolic hepatic steatosis is one of the most prevalent chronic conditions in the world. Systematic reviews estimate that it affects on the order of 30% of the global adult population, closely tracking the epidemics of obesity and type 2 diabetes (Younossi et al., 2023).
This figure repositions the disease: it is not a rare incidental ultrasound finding, but a systemic public health problem anchored in metabolism. The high prevalence also explains why the mere presence of hepatic fat, in isolation, has limited prognostic value — being so common, it must be qualified by other markers to separate those who are at risk from those who merely share a frequent metabolic trait.
The mechanism: ectopic lipid and insulin resistance
Hepatic fat is at once a marker and a participant in metabolic dysfunction.
Why does fat deposit in the liver, and why does that matter? The central concept is that of ectopic lipid: fat accumulated in a tissue that is not adipose tissue. In the hepatocyte, lipid species such as diacylglycerol interfere with insulin signaling, contributing to hepatic resistance to this hormone (Petersen & Shulman, 2018).
This physiology underpins the association between hepatic fat and metabolic dysfunction in both directions. Steatosis functions as a marker of an unfavorable metabolic environment and, at the same time, as an active participant in the insulin resistance circuit. That is why the fatty liver rarely travels alone: it usually comes accompanied by glycemic, blood pressure, and lipid abnormalities — the same criteria that define MASLD.
Cardiometabolic risk: association, not a causal verdict
The leading cause of death in these patients is cardiovascular, not hepatic.
A frequently underestimated point: in patients with metabolic steatosis, cardiovascular disease — and not liver disease — is usually the leading cause of death. Meta-analyses of observational studies show that steatotic liver disease is associated with about double the risk of incident fatal and non-fatal cardiovascular events (Targher et al., 2016).
This number must be read rigorously. It is an observational association, not proof of causation. The risk factors that accompany steatosis — obesity, diabetes, dyslipidemia, hypertension — are shared confounders and also drive cardiovascular risk in their own right. The correct reading is that hepatic fat signals a cardiometabolically more vulnerable patient, not that fat in the liver, by itself, causes the heart attack. This distinction shifts the focus of management: caring for global risk, and not just the liver.
What dictates hepatic prognosis is fibrosis
Mild steatosis is not the same as advanced fibrosis — and vice versa.
Not all fat in the liver carries the same weight. It is essential to distinguish three situations that are often mistakenly treated as synonyms: simple steatosis (fat without relevant inflammation), steatohepatitis (MASH, with inflammation and hepatocyte injury), and fibrosis (progressive scarring of the tissue). What determines hepatic prognosis is the fibrosis stage, and not the mere presence of fat.
For this reason, the guidelines of scientific societies recommend starting with risk stratification using non-invasive tests, such as the FIB-4 score and hepatic elastography, reserving additional evaluation for those who show signs of fibrosis (EASL-EASD-EASO, 2024). These tests have limits — false positives and negatives exist — and do not replace clinical judgment. The practical implication is twofold: one should neither alarm those who have only mild steatosis, nor minimize those who already present with fibrosis. Self-diagnosis by isolated imaging does not allow this distinction.
Evidence-based management: lifestyle first
Weight loss and exercise are the foundation; the approved drug is a complement, not a substitute.
The first-line intervention is lifestyle modification, with diet and exercise at the center (EASL-EASD-EASO, 2024). Weight loss shows a dose-response relationship with histological improvement: in a prospective study with paired biopsies, more substantial weight losses were associated with a higher rate of steatohepatitis resolution and even fibrosis regression in most of those who reached the highest targets (Vilar-Gomez et al., 2015).
Two honest caveats accompany this finding. First, the benefit is proportional: smaller losses bring smaller benefits, and there is no guarantee of reversal. Second, only a minority of patients sustain losses of 10% or more over the long term — a reason to calibrate expectations and avoid promises of results. Diet and activity goals must be individualized, with no single protocol for everyone.
Exercise deserves its own emphasis: a randomized trial showed that aerobic training reduces hepatic fat and visceral adiposity even without clinically significant weight loss (Keating et al., 2015). In other words, physical activity is worthwhile in itself, regardless of what the scale shows.
On the pharmacological front, 2024 brought a milestone: resmetirom, a hepatic thyroid hormone receptor agonist, was the first drug to demonstrate, in a phase 3 trial, improvement in histological outcomes — resolution of MASH and improvement of fibrosis — obtaining regulatory approval for MASH with fibrosis (Harrison et al., 2024). The correct framing: the outcomes were histological (surrogate), the indication is restricted to MASH with fibrosis and under specialized prescription, still without long-term mortality data. The drug complements — it does not replace — diet and exercise.
| Magnitude of weight loss | Expected histological benefit |
|---|---|
| Less than 5% | Limited benefit; partial improvement of steatosis in some cases |
| 5% to 7% | Improvement of steatosis and inflammation in an increasing proportion |
| 7% to 10% | Resolution of MASH in a substantial share of those who reach the target |
| >= 10% | Higher rate of MASH resolution and possibility of fibrosis regression in most of those who achieve it |
Why this matters for your care
This content is strictly educational in purpose and does not replace individualized medical consultation, diagnosis, or treatment. The associations described — especially those regarding cardiovascular risk — derive from observational studies and do not prove causation; goals for diet, exercise, and any pharmacological therapy must be defined case by case by a qualified professional, in accordance with CFM regulations. If you want to better understand your own metabolic signals before talking to your doctor, start with the Functional Self-Assessment and explore related topics in the Library.
References
- Rinella ME, Lazarus JV, Ratziu V, Francque SM, et al. (multisociety Delphi panel). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology (2023;78:1966-1986). 2023. doi:10.1097/HEP.0000000000000520
- Younossi ZM, Golabi P, Paik JM, Henry A, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (2023;77:1335-1347). 2023. doi:10.1097/HEP.0000000000000004
- Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiological Reviews (2018;98:2133-2223). 2018. doi:10.1152/physrev.00063.2017
- Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology (2016;65:589-600). 2016. doi:10.1016/j.jhep.2016.05.013
- European Association for the Study of the Liver (EASL), EASD, EASO; Tacke F, et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology (2024;81:492-542). 2024. doi:10.1016/j.jhep.2024.04.031
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology (2015;149:367-378). 2015. doi:10.1053/j.gastro.2015.04.005
- Keating SE, Hackett DA, Parker HM, O'Connor HT, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. Journal of Hepatology (2015;63:174-182). 2015. doi:10.1016/j.jhep.2015.02.022
- Harrison SA, Bedossa P, Guy CD, Schattenberg JM, et al. (MAESTRO-NASH). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine (2024;390:497-509). 2024. doi:10.1056/NEJMoa2309000
Educational and scientific content. It does not constitute diagnosis, prescription or individual clinical guidance, and does not replace a medical consultation. Management decisions must be individualized by a physician.